Lilly gains Prozac indications
This article was originally published in Pharmaceutical Approvals Monthly
Lilly's Prozac (fluoxetine) gains additional indications July 29 for panic disorder, with and without agoraphobia, and longer-term treatment of bulimia. Labeling adds 52-week follow-up data to existing 16-week studies in bulimia; the panic studies were 12 weeks long. Lilly had expected Prozac exclusivity to run until June 2004, but a court decision in August 2001 invalidated its longest-running patents, allowing generics to come to marke
You may also be interested in...
Pear Therapeutics’ Somryst insomnia treatment tool has become the first FDA-cleared product that was reviewed through the agency’s Software Precertification Pilot Program.
CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.
The AAM has warned the Trump administration that ‘Buy American’ requirements on medicines could limit patient access to affordable medicines and increase the risk of drug shortages during the coronavirus pandemic.